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1
2,4-DISULFONYL PHENYL BUTYL
NITRONE, ITS SALTS, AND THEIR USE AS
PHARMACEUTICALS

CROSS-REFERENCE TO RELATED
APPLICATIONS

The present application is a divisional application of
application Ser. No. 08/173,579, ?led Dec. 23, 1993.
BACKGROUND INFORMATION
This invention relates to a particular nitrone compound
and its salts and their advantageous use as pharmaceutical

and n is a whole integer from 1 to 5 or

nitrone free radical trapping agents.
BACKGROUND INFORMATION

Alpha-phenyl tert butyl nitrone
and Y is tert-butyl or a hydroxylated or acetylated tert-butyl
or a substituted phenyl. These compounds were proposed as

pharmaceutical agents to treat the aftermath of stroke and
other conditions reported to be associated with free radical

damage.
or “PBN“) was identi?ed in the 1970s as a useful analytical

In 1992 a second PCT patent application was ?led
reagent to be used in conjunction with electron spin reso
directed to PBN ant related compounds and their medical
nance (“ESR”) to aid in the detection of free radicals, PBN 30 use. This application, based on prior U.S. patent application
was found to react with certain free radicals and generate a
Ser. No. 716,952 (?led Jun. 18, 1991), was published on
chemical species yielding a characteristic ESR spectrum and
Dec. 23, 1992 as WO 92122290. This 1992 publication
thus making it possible to determine the presence or absence
provided two extremely broad and general disclosures. First,
of free radicals.
In the late 1970s and early 1980s the medical community 35 it attempted to describe as many disease states as possible
began to focus on the roles played by free radicals in
which were associated with free radicals. These ranged from
diseases such as heart attacks, strokes and the like. PBN was

CNS conditions (including stroke, aging, migraine, etc.)
through peripheral organ disease (including atherosclerosis,

used increasingly in vitro to provide analytical evidence of
the presence of free radicals in these settings. It was also
later administered in vivo in animal models, again as an

bed sores, wounds, and muscle overexertion) through UV
analytical adjunct in attempts to observe free radicals during 40 exposure, to mention but a few highlights. Second, it
attempted to list as many potential spin traps as possible.
ischemia simulations and the like.
In addition to a whole range of non-PBN materials, this
In the mid 1980s, the ?rst possible therapeutic effects of
PBN were implied when severe trauma ischernia animal
tests showed that PBN-treated animals were more likely to 45

survive than controls.

application greatly expanded the de?nition of potentially
useful PBN compounds to include PBN, and derivatives
thereof of the formula

On May 2, 1991, PCT patent application WO—9l-05552
was published. This patent application, which in part cor—
responds to now-issued U.S. Pat. Nos. 5,825,032 and 5,036,
097, described PBN and a family of PBN derivatives de?ned
by the formula

H

55

wherein
X is phenyl, imidazolyl, phenothiazinyl 0

wherein
X is phenyl o
60

(011)"

n=-5, preferably 1-3;
65
where R is H

R2=independently (can vary within the molecule) halo

gen, alkyl, oxvalkyl, alkenyl, oxyalkenyl, OH, NH2,
NI-IZ, N22, NO,

5,475,032
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tain their ratio of therapeutic potency to toxicity. In contrast,
the compound of this invention deviates from this expected
relationship when its potency increased and its toxicity
decreased relative to closely related analogs.
Accordingly, in one aspect, the invention provides the

PBN-disulfonyl compound

—SO3H, ——OSO3H, SH, —S(alkyl), —S(alkenyl, and
haloalkyl, speci?cally including —CF3;
A:0 or S; and

SOQH

Z is a C1 to C6 straight, branched, alkyl or cyclic group;

and its pharmaceutically acceptable salts.

and

In a second aspect, the invention provides parenterally-,

Y is a tert-butyl group that can be hydroxylated or
acetylated at one or more positions; phenyl or

e.g. intravenously- and orally-administrable pharmaceutical
compositions having this compound or its salt as active

ingredient.

(R2),

20

In a third aspect, this invention provides a method for

treating a patient who is suffering from a condition involving
acute oxidative damage to the central nervous system, such
as a patient who has suffered a stroke, in which a pharma
ceutical composition based on this compound or its salt is

PBN was stated to be the most preferred compound at that 25 administered parenterally, e.g. intravenously.
time, being said to have no measurable e?‘ect on normal or
In a fourth aspect, this invention provides a method for
treating a patient suffering from a condition characterized by
uninjured cells, and a number of derivatives were also stated
protracted low grade oxidative stress upon the central ner
to be useful, including hydroxy derivatives, especially 2-, 3
vous system and progressive loss of central nervous system
or 4-hydroxyphenyl t-butyl nitrone and phenyl (mono-, di

or trihydroxy) tert-butyl nitrone; PBN esters, especially
esters which release 2-, 3-, or 4-hydroxyphenyl t-butyl

30

function. In this method, a pharmaceutical composition
based on this compound or its salt is administered parenter

ally, e.g. intravenously or preferably orally.

nitrone such as acetoxy derivative; 2-, 3-, or 4-carboxyphe

nyl t~butyl nitrone; phenyl hydroxybutyl nitrone; alkoxyl

In a ?fth aspect, this invention provides a method for

derivatives, especially alkoxyl derivatives which release 2-,
3-, or 4-hydroxyphenyl t-butyl nitrone, for example, the 2-,

reducing or ameliorating the side-eifects arising from oxi
dative damage produced in a patient by cancer therapy. In
this method a pharmaceutical composition based on this
compound or its salt is administered parenterally, e.g. intra
venously or orally.

35

3-, or 4-methoxyphenyl derivatives of PBN; and acetamide
derivatives, especially acetarnide derivatives which release

2-, 3-, or 4-aminophenyl t-butyl nitrone; diphenyl nitrone
(PPN) and the analogous diphenyl nitrone derivatives;
N-tert-butyl-u-(4-nitrophenyl) nitrone; and N-tert-butyl-tx
(Z-sulfophenyl) nitrone.

40

DETAILED DESCRIPTION OF THE
INVENTION

This Detailed Description is arranged into the following
STATEMENT OF THE INVENTION

sections:

Brief Description of Drawings.

It has now been discovered that one particular PBN

The Compounds and Salts.

derivative and its salts have unexpectedly superior pharma

cological properties. Although this derivative, 2,4-disulfonyl

Compound Preparation.

PBN, falls within the broad family of materials generally
described in the aforementioned WO 92/022290 publication,

Pharmaceutical Compositions.
Conditions Treated and Treatment Regimens.

it is not speci?cally disclosed. Neither are its advantageous

Examples.

properties predicted.
The present compound with its two sulfonate groups was
expected to exhibit improved water solubility but was also
expected to exhibit poor transport across the blood/brain
barrier because of its lipophobic character. However, when
the present compound was made and tested in vivo, it
showed an unexpected increase in e?icacy as compared to
PBN. This increase in eliicacy occurred along with an
increase in potency as compared to PBN. In direct contrast
to this marked increase in potency and e?icacy there was a
marked and highly signi?cant decrease in toxicity as com
pared to PBN.

These results were unexpected because in the general
literature on structure/activity relationships within speci?c

de?ned families of compounds therapeutic potency typically
covaries with toxicity. Thus, most related compounds main

BRIEF DESCRIPTION OF THE DRAWINGS
55

In this speci?cation reference will be made to the accom

panying drawings in which
FIG. 1 is a schematic ?ow chart of the reactions used to

prepare the compound.
60

FIGS. 2 (A, B and C) and 3 (A, B, C, and D) are two sets

of graphs illustrating the undesirable change in animal body
thermal regulatory ability which occurs as a function of dose

65

level with a prior art nitrone radical trapping agent and
contrasting this with the lack of such undesired toxic effect
with the compound of the invention.
FIG. 4 (A, B, C, and D) is a set of four graphs demon
strating the superiority of the compound of the invention as

5,475,032
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6

compared to a closely related prior art nitrone compound in
the treatment of gradual neurodegeneration conditions (such

to the corresponding n-hydroxyl amine using a suitable
catalyst such as an activated zinc/acetic acid catalyst or an

as Alzheimer’ s disease) as illustrated by their relative ability

aluminum/mercury amalgam catalyst. This reaction can be

to interfere with beta amyloid protein‘s inactivation of key

carried out in 0.5 to 12 hours and especially about 2 to 6

enzymes in solution.
FIG. 5 is a graph illustrating the effectiveness of the

liquid reaction medium such as alcohol/water mixture in the

hours or so at a temperature of about 15° to 100° C. in a

case of the zinc catalyst or an ether/water mixture in the case

compound of the invention in reducing the ultimate infarct
volume observed following middle cerebral artery occlusion

of the aluminum amalgam catalyst.
In the second step, the freshly formed hydroxylamine is

in rats.

FIGS. 6 (A, B and C) are three graphs illustrating the
ability of the compound of the invention to reduce the
side-effects in animals of high dose levels of anticancer

reacted with 4-formyl-l ,3 -benzenedisulfonic acid, typically

agents.

reaction is generally complete in 10 to 24 hours.
The product so formed is the free acid and is characterized
by a molecular weight of 89 g/mole. It is a white powdery
material which decomposes upon heating. It is characterized
by a solubility in water of greater than 1 gram/ml and a 1H
NMR spectrum in D20 of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836
ppm ((1, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s).
The various salts can be easily formed by admixing the
free acid in aqueous medium with two equivalents of the

THE COMPOUND AND SALTS

with a slight excess of the amine being used. This reaction
can be carried out at similar temperature conditions. This
15

The compound of this invention is 2,4-disulfonyl ot-phe
nyl tertiary butyl nitrone. It is also referred to informally
herein as “2,4-disulfonyl PBN” or “PBN 2,4-disulfonate." It
exists in an acid form

appropriate base, for example, KOH for the potassium salt,
and the like.
PHARMACEUTICAL COMPOSITIONS

The compound (including its salts) can be formulated into
pharmaceutical compositions suitable for oral or parenteral,

as a solid and in solution in low pH conditions. It also exists
e.g. intravenous or intramuscular injection administration.
at higher pHs in an ionized salt form which can be shown as 30
The compositions for oral administration can take the

form of liquid solutions or suspensions, powders, tablets,
capsules or the like. In such compositions, the PBN 2,4»
disulfonate or its salt is usually a minor component (0.1 to

say 50% by weight) with the remainder being various
vehicles or carriers and processing aids helpful for forming
the desired dosing form. A liquid form may include a
suitable aqueous or nonaqueous vehicle with buffers, sus

pending dispensing agents, colorants. flavors and the like.
40

A solid form may include, for example, any of the
following ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat

ing agent such as alginic acid, Primogel, or corn starch; a
45

where X is a pharmaceutically acceptable cation. Most
commonly, this cation is a monovalent material such as
sodium, potassium or ammonium, but it can also be a
multivalent alone or cation in combination with a pharma

methyl salicylate, or orange ?avoring.

ceutically acceptable monovalent anion, for example cal
cium with a chloride, bromide, iodide, hydroxyl, nitrate,
sulfonate, acetate, tartrate, oxalate, succinate, palmoate or
the like anion; magnesium with such anions; zinc with such
anions or the like. When these combinations of a polyvalent
cation and a monovalent anion are illustrated in structural 55

Among these materials, the free acid and the simple
sodium, potassium or ammonium salts are most preferred
but somewhat less so.

60

COMPOUND PREPARATION

As detailed in FIG. 1 and demonstrated in Example 1, the
compound of this invention can be prepared by a two step
reaction sequence. In the ?rst step, commercially available

tertiary butyl nitrate (2 -methyl-2-nitropropane) is converted

In the case of injectable compositions, they are commonly
based upon injectable sterile saline or phosphate-bu?’ered
saline or other injectable carriers known in the art. Again the
active nitrone is typically a minor component, often being
from about 0.05 to 10% by weight with the remainder being
the injectable carrier and the like.
CONDITIONS TREATED AND TREATMENT
REGIMENS

formulae, herein, the monovalent anion is identi?ed as “Y”.

with the calcium and magnesium salts also being preferred

lubricant such as magnesium stearate; a glidant such as
colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint, sugar,

65

The conditions treated with the 2,4-disulfonyl PBN gen
erally fall into three groups. The ?rst includes conditions
involving acute intense oxidative damage to a region of the
central nervous system. Examples of these conditions
include stroke, conditions associated with stroke, concus
sion and subarachnoid hemorrhage. In this setting, the
compound is administered in a manner designed to get the
drug into the patient’s bloodstream as quickly and directly as
possible. This usually means intravenous administration.

5,475,032
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8

Intravenous dose levels for treating these conditions range
from about 0.1 mg/kg/hour to at least 10 mg/kgl'hour, all for
from about 1 to about 120 hours and especially 24 to 96
hours. A preloading bolus of from about 10 to about 500 mg
may also be administered to achieve adequate steady state
levels.

animals it has been observed that the compound of the
invention can improve patient tolerance of these antine
oplastic disease treatments.
In this therapy, the compound of the invention may be
administered before, during and after the radiation or che
motherapy is administered. Administration may be
parenteral or oral or by any other method which will permit
the 2,4~disulfonate PBN to enter the patient’s bloodstream.

While intravenous administration is preferred, other
forms of parenteral administration, such as intramuscular
injection can be used, as well. In this case, similar dose

A positive dose-response relationship has been observed.

levels are employed. An unexpected and key advantage of

As such, and bearing in mind the severity of the side effects

2,4-disulfonyl PBN is that it can be administered at vastly
higher levels than are possible with PBN itself. As will be
shown in the Examples, doses of up to 1000 mg/kg/hour and
higher or intravenous bolus doses of from 10 to 2500 mg/kg

and the advantages of providing maximum possible protec
tion or amelioration, it may be desired in some settings to

administer large amounts of 2,4 -disulfonyl PBN such as
those described above for the acute intense oxidative CNS

have been demonstrated to be possible with 2,4-disulfonyl

damage conditions. In other settings lower doses, such as
those set forth for the progressive neuronal disease therapy,

PBN or its salts while with PBN itself death or acute toxicity
results from such doses. With 2,4-disulfonyl PBN there is an

may be used.

unexpected positive continuance of the dose/response curve
in these high dose levels with the clear message that intense
heavy dosing immediately post stroke or other trauma may
in many cases provide a major positive impact upon recov

20

cry.

The second group of conditions which respond favorably
to 2,4-disulfonyl PBN treatment are conditions character

ized by protracted low grade oxidative stress upon the
central nervous system and gradual progressive central

25

every seven or twenty-one days. Compound I may be
administered before the adriamycin, for example, up to 60
minutes before, at the same time or after, such as hours after

lower for both drugs. Higher doses may be used for treat

Alzheimer’s disease, Parkinson‘s disease, amyotrophic lat
eral sclerosis (ALS), multidnfarct dementia, retinopathy and

ment of multidose resistant tumors.
30

progressive loss of function. 2,4-disulfonyl-PBN or its salts,
when administered orally or parenterally, e.g. intravenously,
can slow and possibly reverse the loss of function. If

parenteral, e. g. intravenous administration is desired, similar
levels to those used with acute conditions but at the lower
end of the ranges are generally used.
In these cases, the regimen for treatment may stretch over
many months or years so oral dosing is preferred for patient
convenience and tolerance. With oral dosing, one to three
oral doses per day, each from about 0.02 to about 50 mg/kg
are called for with preferred doses being from about 0.04 to

representative dose combinations are 10-600 mg Compound
I per square meter area plus 60 mg adriamycin per square
meter of surface area with adriamycin dosing occurring

and on subsequent days. The pediatric dose is typically

nervous system function loss. These conditions include

the like. Each of these conditions is characterized by a

The following are examples of representative administra~
tion regimens: In monotherapy (adriarnycin alone) two

35

EXAMPLES

Example 1
Synthesis of 2,4-disulfonylphenyl-N-t-butylnitrone
(Compound “I” in subsequent Examples). This preferred
synthesis is based on the work by R. H., Hinton and E. G.

Janzen (J. Org. Chem,. 57:2646—265l, 1992). As shown in
FIG. 1 it involves the condensation of an aldehyde with a

hydroxylamine. The hydroxylamine is unstable and is pre
40

pared fresh on the day of use using an activated zinc catalyst.
The synthesis is as follows:

about 5.0 mg/kg.
Of course, one can administer 2,4-disulfonyl PBN as the
sole active agent or one can administer it in combination 45

with other agents. This leads to a third application for this

POQCKUi-ALDMH

. Zinc dust

A third set of conditions which respond to treatment with
2,4-disulfonyl PBN are the side-effects which arise in

. Glacial acetic acid

50

. Diethyl ether
. Saturated sodium chloride

. Magnesium Sulfate, Anhydrous solid

dative~damage causing chemotherapeutic agents. Examples
of these agents include antibiotics such as daunorubicin,

. 95% Ethanol
. 2-Methyl-2-nitropropane

compound.
patients from oxidative damage produced by cancer (neo
plastic disease) therapy. The therapy which produces the
oxidative damage (and thus the side effects) includes radia
tion (e.g. gamma radiation) therapy and therapy with oxi

Prerequisite Chemicals

55

doxorubicin and bleornycin; procarbazine; nitrogen mus
tards such as ifosfamide, melphalan and chlorambucil; alky

4-Formyl- l ,3-benzenesulfonic acid (MW 310.21
g/mole), disodium salt, hydrate

9. Methanol
l0. Dichloromethane

lating agents; antimetabolites; hormones and antagonists.
Procedure

Administration of 2,4-disulfonyl PBN can have the effect

of reducing patient discomfort during these therapies. In
addition, administration of the compound of this invention
can increasing patients’ ability to tolerate these therapies.
Often the side effects of therapies force the discontinuance
of these therapies or prevent the administration of optimal
high doses or rapid frequencies of these therapies. In some
cases these side effects are devastatingly destructive and
lead to heart failure and other major function loss. In tests in

60

A. Preparation of N-t-Butylhydroxylamine
l. A 500 ml three neck round bottom ?ask is equipped

65

with a magnetic stir bar, thermometer adapter, ther
mometer, and addition funnel.
2. 95% ethanol (350 ml) was added to the ?ask and cooled
to 10° C. in an ice bath.

3. 2-Methyl-2-nitropropane (6.18 g, 0.060 mole), and zinc

5,475,032
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. Mercury (II) Chloride (9.68 g in 476 ml water)

dust (5.89 g, 0.090 mole) were added in single portions.
4. Glacial acetic acid (10.8 g, 0.180 mole) was placed in

. Ethanol

the addition funnel and added dropwise at such a rate

. Ether (6 l)

with vigorous stirring to maintain the temperature

. Pure Water

below 15° C.

. 2-Methyl-2-nitropropane

5. The ice bath was removed and mixture was stirred for
3 hrs at room temperature.

. Sodium Hydroxide, 2M (80 g in l 1 water)
. Magnesium Sulfate, Anhydrous solid

6. The solvent was stripped from the mixture, leaving
t-butylhydroxylamine, zinc acetate, and water.
7. Dichloromethane (50 ml) was added and the mixture
?ltered through a Buchner funnel.

4-Formyl-l,3-benzenesulfonic acid (MW 310.21

g/mole)
Procedure

8. The zinc acetate cake left on the ?lter paper was washed

with 2X25 ml dichloromethane.
9. Water was separated from the ?ltrate in a separatory

A, Preparation of N-t-Butylhydroxylamine

funnel and the organic layer dried over magnesium

1. Aluminum foil cylinders were dipped into HgCl2
solution for 15-30 seconds, then dipped in ethanol,

sulfate.
10. The magnesium sulfate was removed by ?ltering
through ?uted ?lter paper, then dichloromethane

then dipped in ether and then placed into a 5 l ?ask
containing 500 ml of diethyl ether and 21.4 ml of water.

stripped o? by rotary evaporation.
11. The product (100% yield=5.34 g), a viscous liquid,

20

2. The ?ask was ?tted with a 250 ml pressure-equalizing

dropping funnel, a mechanical stirrer, a nitrogen inlet,
and a Friedrichs condenser cooled with recirculated ice

was dissolved in methanol (50 ml) for use in part B.

water.

B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone

3. The mixture was stirred for 10 minutes.

l. A 3-r1eck 250 ml round bottom ?ask was set up with a 25

4. 2-Methyl-2-nitropropane (71.68 g, 75.5 ml) was added

stir bar, a gas dispersion tube, an addition funnel, and
a Friedrichs condenser cooled with recirculating ice

using the dropping funnel at such a rate as to maintain
a vigorous re?ux.

water.

NOTE: Addition must be completed in less than 20 minutes
or the yield drops signi?cantly.

2. To the ?ask were added 200 ml of methanol, 4-for'myl

1,3-benzenedisulfonic acid (9.31 g, 30 mmoles) and
N-t-butylhydroxylamine (25 ml of the methanol solu
tion from part A, 30 moles theoretical).

30

5. As the addition proceeded, ether was added in 500 ml
portions. This was done to maintain as high a concen

tration of product as possible without the formation of

3. The reaction was heated to re?ux with a heating mantle

while bubbling the reaction with nitrogen with stirring.
35
4. The mixture was re?uxed for 2 hours.
5. The remainder of hydroxylamine from part A was
added.

6. Re?uxing was continued with nitrogen bubbling for at
least 18 hours, but not more than 24 hours.
40
7. The hot reaction mixture was ?ltered on a Buchner

funnel, and the solid washed with hot methanol.
8. The methanol was stripped off by rotary evaporation to

a gel. Up to 2 l of ether can be added with no deleterious
effects on the yield.
6. Once addition of 2-methyl-2-nitropropane was com
plete, the reaction was stirred for an additional 30
minutes.
7. The resulting gray suspension was suction ?ltered in 3
batches to remove aluminum salts.
8. Each ?lter cake was washed with l l of ether.
9. The combined either layers were washed with 300 ml

of 2M NaOH, then dried (MgSO4), and concentrated in

a yellow. viscous oil.
9. Hot 1:1 ethanol:acetone (200 ml) was added and the
mixture heated to dissolve the oil.
10. The solution was cooled to crystallize the product.
11. The product was collected on a Buchner funnel and
dried under vacuum overnight.
50

12. The reaction typically gives 75% yield of Compound
I, a white powder.

vacuo to leave a soft white solid.

10. The solid melts just above room temperature, but
could be dried further in a vacuum oven (no more than

a few minutes), leaving 38 to 45 g of solid.
11. The solid can be used as is or was puri?ed by

recrystallization from pentane.
12. Molecular weight-89 g/mole.
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone
l. A 250 ml ?ask was equipped with a stir bar and a

Friedrichs condenser cooled with recirculated ice

Example 2
55

Alternate Synthesis of 2,4—disulfonylphenyl-N-t-butylni
trone (Compound I). This is an earlier-developed method
which used to prepare samples of the compound used in
several of the experiments reported in the Examples of this
speci?cation. The product of this Example is identical in all
ways to the product of Example 1. This synthesis method is

water.

2. The ?ask was charged with 71.8 ml of methanol, 14.5

g of 4-formy1-l,3 -benzenedisulfonic acid (46.7
mmoles, 1 eq.). and 5.0 g of N-t-butylhydroxylamine

(56.2 mmoles, 1.2 eq.).
60

as follows:

3. The mixture was re?uxed overnight.
4. The reaction product was transferred to round-bottom

?ask and rotovaped to dry.
5. The solid residue was mashed with ether, the ether was

Prerequisite Chemicals
65

1. Aluminum Foil, cut into 5 cm wide strips and rolled in
a ca. 1 cm diameter cylinder

decanted oif (yellow).
6. Step 5 was repeated.
7. Product (“Compound I") was crystallized from metha

5,475,032
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nol following a hot methanol ?ltration to remove

the prior art compounds to go to high doses at which levels

insoluble precipitates and recrystallized twice from

the compound of the invention provides dramatically effec
tive therapy.

methanol.

Example 3

TABLE 2

A series of experiments were carried out to compare in

Neuronal nuclei/100 micron field

vivo the e?icacy of 2,4 disulfonyl PBN (“Compound I”),
PBN, and two monosulfonate PBN compounds as agents for

protecting against neuron loss following brain ischernia and
reperfusion injury. The test procedure is that reported by W.
Cao, J. M. Carney, A. Duchon, R. A. Floyd and M. Chevion

PBN
10

Non-ischemic control

lschemic control

as “Oxygen free radical involvement in ischemia and rep’

erfusion injury to brain, Neuroscience Letters, 88 (1988),

32 mg/kg

233. In the experiments a test compound was administered
to groups of six gerbils i.p. as a single dose 30 min before

50 mglkg

5 min bilateral carotid occlusion. The density of neuronal

100 mg/kg

320 mglkg

present-controls which received no test compound and

ischernia. As illustrated in Table 1. the compound of the
invention showed unexpected advantages as compared to the
prior art compounds. First, it is seen that at low dose levels,
such as 3.2 mg/kg, compound I is 2-3 times as potent at
preventing neuronal loss. At high dose levels it is seen that

Compound I is able to achieve complete protection against

20

signi?cantly lower degrees of protection. These results show

1000 rug/kg

Non-ischemic control

Ischernic control

3.2 rug/kg
10 mglkg

32 mglkg
50 mg/kg

100 mg/kg

3-

Cmpd.
1

4.21

4.21

4.21

4.21

(.43)

(.43)

(.43)

(.43)

058

0.58

0.58

0.58

(.28)

(.28)

(.28)

(.28)

0.43

0.73

0.35

1.43

(.18)

(.34)

(.21)

(.31)

1.13

0.68

0.31

2.57

(.39)

(.31)

(.40)

(.25)

1.83

0.73

1.63

3.53

(.21)

(.31)

(.35)

(.41)

3.11

1.01

1.63

4.11

(.29)

(.61)

(.35)

(.43)

3.68

0.93

1.93

4.18

(.71)

(.53)

(.39)

(.49)

320 mglkg

3.78

1.11

1.78

4.23

(.43)

(.41)

(.40)

(.39)

1000 mg/kg

Toxic

0.98

1.58

4.11

(.43)

(.38)

(.41)

-—-

—~

4.18

3200 mg/kg

Toxic

4.18

4.18

(.59)

(.59)

0.85

0.85

0.85

0.85

(.19)

(.19)

(.19)

(.19)

1.09

ND

ND

1.83

(41)

1.85

0.68

0.73

2.73

(.49)

(.31)

(.34)

(.39)

2.11

0.78

1.09

3.41

(.51)

(.23)

(.48)

(.37)

0.93

2.25

0.81

(-43)

(31)

Toxic

ND

3.55

(48)
ND

3.68

30

35

sulfo

4.18

(.59)

Compound I is compared with PBN to determine the
relative elfectiveness for protection of neuronal loss when
administered i.v. 60 min after reperfusion onset following 5
min ischemia in gerbils using the general test method
described in Example 1.. The results are summarized in
Table 3. and illustrate that compound 1 is of signi?cantly
greater therapeutic bene?t in a clinical treatment setting
following injury to the brain.
TABLE 3

Neuronal nuclei/100 micron ?eld

2

4.18

(.59)

Example 5

TABLE l

sulfo

I

25

pound I compared to PBN and two closely related analogs
and an unexpected decrease in toxicity compared to PBN.

PBN

Cmpd.

(‘39)

neuronal loss as the test brains showed neuronal densities
identical to the non-ischemic controls. The prior art com
pounds are either toxic at these dose levels or showed

a clear increase in potency for neural protection for com

3
sulfo

(.31)

nuclei in a 100 micron was measured. Two controls were

controls which received no test compound and no brain

2
sulfo

mg/kg single dose
N = 6 per group

40

Saline, no ischemia

0.0

0.5

1.0

10

4.11

—

—

—

—

—

~—

(428)
saline, ischemia

0.93

(.17)
PBN

45

—

Compound 1

—

0.83

1.07

1.23

(.23)

(.29)

(.31)

1.25

1.75

2.43

(.19)

(.28)

(.31)

Neither PBN nor Compound I. had an effect on neuronal

density in control gerbils without brain injury.
50

Example 6
Brain injury can manifest itself as behavioral changes. In
55

this experiment, young adult (3-4 months of age) gerbils
were tested to determine their ability to perform an S-ann
maze test 24 hours following an ischemic event as described

Example 4

in Example 1. As compared to nonischemic animals, when

untreated they committed many more errors. PBN and
A series of experiments were conducted in which com
pound l was compared to PBN and two sulfonate analogs in 60 compound I were administered to some of the test animals.

post-ischernia treatment. The general method described in
example 1 was used but the test compounds were adminis

tered i.p. as a single dose 30 min after reperfusion following
5 min ischemia. The results are summarized in Table 2.

Table 2 shows that the compound of the invention is again

65

As detailed in Table 4. gerbils treated with high doses of
compound I had error levels indistinguishable from those of
nonischemic animals. PBN was less eifective. This shows
that compound I can protect against the loss of temporal]
spatial short term memory following ischernia (24 hours

more potent at low doses and more potent and less toxic at

post) errors in S-arm radial maze test of young gerbils

high doses. Also again, toxicity interferes with the ability of

following 5 min ischemia.

5,475,032
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TABLE 4

TABLE 7

mg/kg/hr for 24 hours
N = 6 per group
Control

0.0

L0

32

4.1

—

_

50

% Survival
I00

5

-

(.33)
Postischemic

37.6

—

-—

mg/kg

n = 20 mice

320

560

1000

3000

l0000

PBN

100

25

0

0

0

Compound I

100

100

100

100

100

-—

(4.85)
PBN

—

Compoundl

-

29.3

18.19

6.23

5.83

(7.27)

(5.83)

(.71)

(.49)

14.63

7.19

4.28

4.11

(331)

(.31)

(19)

U9)

10

Example 10
_

Another undesirable systemic effect which has been
observed in vivo with nitrone radical traps is a depression in
body temperature. This toxicity can have serious health
15 consequences and also can complicate diagnosis of other
Example 7
conditions. As detailed in FIGS. 2 and 4, the compound of
this invention was administered to mice and gerbils at levels
The ability of the compound of the invention to reduce
as high as 1000 mg/kg with no measurable temperature
infarct volume following an ischemic event was determined.
decrease_ In contrast’ the compound of the an, pBN’ gave up
As detailed in Table 5. it was observed that while PBN and 20 to an 30 C_ dacrease in body temperature at a does of only
compound I were both effective at low doses, at high doses
500 [mg/kg
I gave the best protection and PBN was toxic. Table 5 shows
the infarct volume observed when test compound was
Example 11
administered i.v. 60 min after middle cerebral occlusion and

continued for 24 hours in C57BU6J mice“

i

25

TABLE 5
Pwmamm
(mg/kw)

Q0

_

_

The compound of the lnvention was tested to detemune
its e?ectiveness in the treatment of conditions characterized

by protracted low grade oxidative stress upon the central

_
Mam v°lume ‘" “"“3
1.0
10
100

nervous system and gradual progressive central nervous
system function loss by testing its effectiveness in a model
30 for Alzheimer’s disease (“AD“). This model has the follow

ing basis: Recent studies have demonstrated that there is an
C‘IPIIDIIYMSCPCmia

0

rr

-

—

age-associated increase in protein oxidation and loss of

same’ ‘Schema
PEN

2(3)
_

—
17.7

—
138

_
Toxic

enzyme activities in the brain of aged individuals. Tissue
cultures of ?broblasts from aged individuals and red blood

Compuuudl

-

(2.8)
16,3
(1'7)

(2.3)
12-7
(3'93)

8-3
(‘71)

Example 8

35 cells of different ages both show an exponential increase in
protein carbonyl content (a measure of protein oxidation)
and a decrease in marker enzyme activities. Brain protein
oxidation progressively increases over the life span of the
individual.

40

In this study, compound I and PBN are compared for their

The role of abnormal amyloid precursor peptide process
ing and metabolism in AD has also been explored in a
number of different models. In vitro studies using embryonic

ability to impart lethality protection (% survived) in aged

hippocarnpal neuronal and nouronallglial cultures have dom

gerbils (18-24 months of age, n=12/gr()up) from 10 min

onstrated that BAP l-40 produces cytotoxicity over an

ischemia when given 30 min before ischemia. As shown in 45 “tended period Of (to-incubation. When this peptide is
Table 6. compound I is superior at all dose levels and
infused into rat brains, lesions are produced. Some of the

achieved complete protection at high levels while PBN is
only partially effective.
TABLE 6

proposed breakdown fragments of BAP are also neurotoxic
[c.g. [SAP (25-35)]. The neurotoxicity appears to be both
mediated via glutamate receptors, and also by non-glutamate
50 receptors mechanisms. Confocal microscopy studies of neu

Pmmatmam
(mg/kg)

ronal cultures_have_ demonstrated that exposure to BAP
on

10

32

m0

320

(1-40) results in oxidative stress [Dichloro?uorescem and

increased intracellular free calcium Fora-2].
gang‘:

4';

—

—

compoundl

_

50

—

“

50

75

92

75

m0

100

It has been demonstrated that BAP fragments can directly
.

55

.

.

.

.

inactivate glutanune synthetase (GS) and creatine kmase

(CK) in tissue extracts and in cultured hippocampal neurons
and glia (See A and B in FIG. 4). A and B of FIG. 4 present

the dose-related inactivation of glutarnine synthetase and
creatine kinase by AP (25-35). Cytosolic fractions from

Exam 1 9
p e

.

.

.

.

60 gerbil neocortex were prepared and enzyme activities deter

An important advantage of the compound of this invention as compared to the art-taught compound, PBN, is its
markedly diminished toxicity. As detailed in Table 7. acute
lethality in C57BL/6L mice was determined based upon
varying sizes of single i.p. doses of nitrone. PBN showed 65

signi?cant toxicity at 560 mg/kg dose levels. Compound I

mined. Samples were incubated in the presence of different
concentrations of the peptide for 10 min prior to assay. Solid
symbols represent the effects of the naturally occurring
25-35 fragment. Open circles indicate that the reverse
sequence (32-25) had no effect on enzyme activity. Open
triangles indicate that the scrambled amino acid sequence

showed no toxicity at doses nearly twenty times as great.

also had no eifect on enzyme activities, compared to the

5,475,032
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eifect of 25-35. Each point is the mean (+/- s.e.) of 5
observations. BAP derived and other cellular sources of free

Adriamycin is a widely used anticancer agent. It is known
to be very effective but it is also known to have serious side

radicals are an important determinant of the initiation and

elfects arising from its tendency to cause oxidative damage.
These side eifects include causing serious levels of cardiac
damage at high dose levels. These side effects have often

progression of AD.
As demonstrated in C and D in FIG. 4, compound I and
PBN each show the ability to protect GS and CK against the
effects of [SAP fragments. C and D of FIG. 4 present the
protective effects of co-incubation of the cytosolic fractions
with BAP 25-35 (0.4 mg/ml) in combination with di?ercnt
concentrations of PBN (open circles) or compound I (closed
circles). Each point is the mean (+/— s.e.) of 3 observations.
As can be seen in C and D, compound I gives complete

limited the use of this agent or limited the dose levels that
can be employed to levels which are below those desired for

maximum antineoplastic disease effectiveness.
Experiments were carried out to demonstrate that the

compound of the invention is e?‘ective at reducing the side
effects of anticancer agents such as adriamycin and permit

ting higher dose levels of adriamycin to be tolerated by

protection and in fact might even be able to reverse the

animals.
C57BL/6l and DBA/2J male mice (35-40 g) were tested
for the acute lethal effects of adriamycin and the prevention

effects of oxidation. In contrast, PBN’s effectiveness is quite
limited as it is asymptotically leveling out at a substantially

incomplete level of protection.

of acute lethality by pretreatment doses of Compound I.
Mice were injected with either saline or Compound I 30

Example 12
Experiments were carried out to further demonstrate the 20

effectiveness of the compound of the invention in preventing
central nervous system damage caused by stroke.

minutes prior to administration of adriamycin. All injections
were intraperitoneal. The acute lethality of adriamycin
ranged from 10 to 30 mglkg. The LDso for adriamycin in
these tests was found to be 25 mglkg in both mouse strains.

Compound I doses up to 300 mglkg, without adriamycin

treatment, had no effect on survival in the two mouse strains.
Rat Focal Ischernia Results.
Pretreatment with 30 and 100 mglkg of Compound I
A pair of studies were done to determine the e?icacy of 25
produced dose related shifts in the adriamycin lethality dose
Compound I in a rat focal ischernia model. In this model,
effect curve. FIG. 6 shows the results obtained using the
Sprague Dawley rats (200-300 g) underwent a permanent
DEA/2] mouse. A dose of 100 mg/kg of Compound I
middle cerebral artery occlusion (MCAO) to induce a focal
produced a 5-fold shift to the right (in the direction of
stroke. Compound I was administered after the permanent
occlusion as ?rst an intraperitoneal (i.p.) bolus dose and then 30 reduced lethality). Thus, the combination of Compound I
with adriamycin resulted in a marked increase in the maxi
by intravenous (i.v.) continuous infusion during the remain
mally tolerated dose. These higher doses are in the range that
ing time up to 24 hours post stroke. The doses of Compound
would elfectively kill multi-drug resistant tumors.
I used were either 100 mg/kg,j.p., followed by 4.2 mglkg/hr,
i.v., or 10 mglkg, i.p., followed by 0.42 mglkg/hr, i.v.
Comparative Tests
The rats were sacri?ced 3 days post stroke, the tissue was 35
PBN pretreatment resulted in a slight shift to the right in
processed histologically using triphenyltetrazolium staining
the adriamycin does-effect curve. While the Compound 1
techniques, and the infarct volume, the area of total cell
dose could be increased to 300 mglkg in combination with

necrosis, was quantitated using image analysis. The results

adriamycin, there was an upper limit for this combination

of these experiments are shown graphically in FIG. 5 and

with PBN. A dose of PBN of 100 mglkg produced slight
sedation and 300 mglkg yielded marked sedation and some

demonstrate that Compound I provided signi?cant protec
tion, approximately 70%, in both studies.
Comparison with Results in the Literature.
Similar data have been reported recently for the com
pound NOT of this invention, PBN, by Cao and Phillis
(Brain Research 664: 267-272, 1994). In their studies, rats
underwent a permanent middle cerebral artery occlusion
(MCAO) and a common carotid artery occlusion. The PBN
was administered i.p. at 100 mglkg at various times post
stroke. The rats were sacri?ced 2 days post stroke and the

infarct volume was quantitated using triphenyltetrazolium

combined toxicity 00-20% lethality). Compound l/adria
mycin did not produce any combined toxicity at doses of
Compound I of up to 300 mglkg.
45

Example 14

Safety Testing.
Compound ] and PBN were tested for their acute toxicity
50

When PBN was administered at 0.5, 5, 17, 29 and 41
hours post stroke, or at 5, 17, 29, and 41 hours post stroke,
the infarct volume was reduced in each case by approxi
mately 50%. The cumulative dose of PBN administered to
achieve 50% protection is at a minimum 4 times the amount

has higher safety than PBN.
What is claimed is:
1. A method for treating a patient who has suffered a

of Compound I required for 70% protection. Thus, Com
pound I is far superior to PBN in offering protection in the
rat MCAO focal ischemia model.

stroke comprising administering to said patient an effective
stroke treating amount of a pharmaceutical composition
60

administered parenterally.

In this Example the compound of this invention (Com

Adriamycin Studies

comprising the compound 2,4-disulfonyl ot-phenyl tertiary
butyl nitrone in a pharmaceutically acceptable carrier.
2. The method of claim 1 wherein the composition is

Example 13
pound I) was evaluated to determine its ability to ameliorate
oxidation-caused side effects of anticancer therapy.

in male Sprague Dawley (200-300 g) rats. The compounds
were administered at 1000 mglkg, i.p., to groups of 6 rats.
After 3 days lethality was assessed. Compound I caused no
lethality, while PBN was lethal to 5 of the 6 rats used in this
test. These data con?rm the gerbil data in that Compound I

stain.

3. The method of claim 2 wherein the composition is
65

administered intravenously.
4. The method of claim 3 wherein the composition is
administered in an amount of at least 0.2 mglkg/hour.

5,475,032
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5. The method of claim 1 wherein the composition is

21. A method for treating a patient su?ering from a
progressive central nervous system function loss comprising
administering to said patient an elfective progressive central
nervous system function loss treating amount of a pharma

administered orally.
6. A method for treating a patient who has su?'ered a

stroke comprising administering to said patient an e?'ective
stroke treating amount of a pharmaceutical composition
comprising a compound of the formula

ceutical composition comprising the compound 2,4-disulfo
nyl ot-phenyl tertiary butyl nitrone in a pharmaceutically
acceptable carrier.
22. The method of claim 21 wherein the composition is

administered parenterally.
23. The method of claim 22 wherein the composition is

administered intravenously.
24. The method of claim 23 wherein the composition is
administered in an amount of at least 0.1 mg/kg/day.

25. The method of claim 21 wherein the composition is

in a pharmaceutically acceptable carrier.
7. The method of claim 6 wherein the composition is

administered orally.

administered parenterally.

26. A method for treating a patient su?ering from a
progressive central nervous system function loss comprising
administering to said patient an effective progressive central

8. The method of claim 7 wherein the composition is

administered intravenously.
9. The method of claim 8 wherein the composition is

nervous system function loss treating amount of a pharma

administered in an amount of at least 0.2 mg/kg/hour.

ceutical composition comprising a compound of the formula

10. The method of claim 6 wherein the composition is

administered orally.
11. A method for treating a patient who has su?ered a

stroke comprising administering to said patient an effective
stroke treating amount of a pharmaceutical composition
comprising a pharmaceutically acceptable salt of

25

in a pharmaceutically acceptable carrier.
27. The method of claim 26 wherein the composition is

administered parenterally.
503

28. The method of claim 27 wherein the composition is

administered intravenously.
in a pharmaceutically acceptable carrier.
12. The method of claim 11 wherein the composition is
admixed parenterally.

35

‘

30. The method of claim 26 wherein the composition is

13. The method of claim 12 wherein the composition is

administered orally.

administered intravenously.
14. The method of claim 13 wherein the composition is

40

administered in an amount of at least 0.2 mg/kglhour.

15. The method of claim 11 wherein the composition is

administered orally.
16. A method for treating a patient who has suffered a
stroke comprising administering to said patient an effective
stroke treating amount of a pharmaceutical composition
comprising a compound of the formula

29. The method of claim 28 wherein the composition is
administered in an amount of at least 0.1 mg/kglday.

31. A method for treating a patient suifering from a
progressive central nervous system function loss comprising
administering to said patient an e?°ective progressive central
nervous system function loss treating amount of a pharma

ceutical composition comprising a pharmaceutically accept
45

able salt of
O

$034
803x
55

administered parenterally.

wherein X is selected from the group consisting of Na, K,
NH4, Ca Mg, Zn, ZnY, CaY and MgY, wherein Y is a
pharmaceutically acceptable monovalent anion, in a phar~

33. The method of claim 32 wherein the composition is

administered intravenously.

maceutically acceptable carrier.

34. The method of claim 33 wherein the composition is

17. The method of claim 16 wherein the composition is

administered in an amount of at least 0.1 mg/kg/day.

administered parenterally.

35. The method of claim 31 wherein the composition is

administered orally.

18. The method of claim 17 wherein the composition is

administered intravenously.
19. The method of claim 18 wherein the composition is
administered in an amount of at least 0.2 mg/kg/hour.

20. The method of claim 16 wherein the composition is

administered orally.

in a pharmaceutically acceptable carrier.
32. The method of claim 31 wherein the composition is

65

36. A method for treating a patient suffering from a
progressive central nervous system function loss comprising
administering to said patient an e?’ective progressive central
nervous system function loss treating amount of a pharma—

ceutical composition comprising a compound of the formula

5,475,032
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maceutically acceptable canier.
37. The method of claim 36 wherein the composition is

administered parenterally.
38. The method of claim 37 wherein the composition is

administered intravenously.
39. The method of claim 38 wherein the composition is
administered in an amount of at least 0.1 mglkg/day.

40. The method of claim 36 wherein the composition is
administered orally.
wherein X is selected from the group consisting of Na, K,
NH4, Ca, Mg, Zn, Zny, CaY and MgY, wherein Y is a 10
pharmaceutically acceptable monovalent anion, in a phar
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corrected as shown below:

Column 4, line 6,

"PBN——disulfonyl" should read ——PBN

disulfo—-.

Column 5, line 17,

"2,4-disulfonyl" should read --2,4—

Column 5, line 19,

"2,4-disulfonyl PBN" should read

disulfo——.

--2,4-disulfo PBN——.
Column 6, line 59,

"2,4-disulfonyl"

should read

Column 7, line 11,

"2,4-disulfonyl‘l

should read

line l5,

"2,4-disulfonyl"

should read

line 17,

"2,4-disulfonyl"

should read

line 24,

"2,4-disulfonyl"

should read

disulfo—-.
disulfo——.

Column 7,

disulfo--.
Column

disulfo—-.
Column

disulfo—-.
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It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby
corrected as shown below:

Column 7, line 31, "2,4—disulfonyl-PBN" should read

-—2,4—disulfo—PBN—-.
Column 7, line 43, "2,4-disulfonyl" should read —-2,4—
disulfo—-.

Column 7, line 48, "2,4-disulfonyl" should read --2,4—
disulfo-—.
Column 7, line 59, "2,4-disulfonyl" should read —-2,4
disulfo--.
Column 8, line 13, "2,4—disulfonyl" should read -—2,4—
disulfo—-.

Column 8, line 34, "2,4-disulfonylphenyl-N-t
butylnitrone" should read --2,4-disulfophenyl—N-t

butylnitrone——.

Column 9, lines 56-57, "2,4-disulfonylphenyl-N-t
butylnitrone" should read —-2,4-disulfophenyl—N-t—

butylnitrone—-.

Column 10, line 51, "2,4-disulfonylphenyl-N-t
butylnitrone" should read -—2,4—disulfophenyl—N-t—

butylnitrone--.

